

Supplementary Materials

Parkinson's Families Project: a UK-wide study of early onset and familial Parkinson's disease

Theresa M. Schmaderer*, Clodagh Towns*, Simona Jasaityte, Manuela M. X. Tan, Miriam Pollard, Megan Hodgson, Lesley Wu, Russel Tilney, Robyn Labrum, Jason Hehir, James Polke, Kailash P. Bhatia, Henry Houlden, Nicholas Wood, Paul R. Jarman, Huw R. Morris[^], Raquel Real[^], on behalf of the PFP Study Group

*These authors contributed equally to this work.

[^] Joint senior authors.

Table of Contents

PFP Study Group	3
Supplementary Figure 1.....	5
Supplementary Figure 2.....	6
Supplementary Table 1.....	7
Supplementary Table 2.....	9
Supplementary Table 3.....	10
Supplementary Table 4.....	11
Supplementary Table 5.....	12
Supplementary Table 6.....	13
Supplementary Table 7.....	14

PFP Study Group


Lead Investigators: Prof Huw R. Morris (UCL Queen Square Institute of Neurology), Dr Paul Jarman (National Hospital for Neurology and Neurosurgery), Prof Henry Houlden (UCL Queen Square Institute of Neurology), Prof Nicholas W. Wood (UCL Queen Square Institute of Neurology), Dr Raquel Real (UCL Queen Square Institute of Neurology)

Co-Investigators: Manuela Tan (UCL Queen Square Institute of Neurology), Russel Tilney (UCL Queen Square Institute of Neurology)


Principal investigators for sites: Huw R. Morris (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust), Elizabeth Wakeman (Isle of Wight NHS Trust), Tabish Saifee (London North West Healthcare NHS Trust), Sam Arianayagam (Hampshire Hospitals NHS Foundation Trust), Saifuddin Shaik (Lancashire Teaching Hospitals NHS Trust), Sophie Molloy (Imperial College Healthcare NHS Trust and London North West Healthcare NHS Trust), Ralph Gregory (University Hospitals Dorset NHS Foundation Trust), Mirdhu Wickremaratchi (Western Sussex Hospitals NHS Foundation Trust), Rosaria Buccoliero (Harrogate and District NHS Foundation Trust), Oliver Bandmann (Sheffield Teaching Hospital NHS Foundation Trust), Dominic Paviour (St George's University Hospitals NHS Foundation Trust), Diran Padiachy (Salisbury NHS Foundation Trust), Anjum Misbahuddin (Barking, Havering and Redbridge University Hospitals NHS Trust), Jeremy Cosgrove (Leeds Teaching Hospitals NHS Trust), Sunku Guptha (North West Anglia NHS Foundation Trust), Ray Chaudhuri (King's College Hospital NHS Foundation Trust), Yen Tai (The Hillingdon Hospitals NHS Foundation Trust), Sukaina Asad (University Hospitals of Leicester NHS Trust), Ayano Funaki (Central London Community Healthcare NHS Trust), Marek Kunc (Airedale NHS Foundation Trust), Charlotte Brierley (West Suffolk NHS Foundation Trust), Ray Sheridan (Royal Devon & Exeter NHS Foundation Trust), Rena Truscott (Livewell Southwest), Suzanne Dean (Royal Cornwall Hospitals NHS Trust), Carinna Vickers (Somerset NHS Foundation Trust), Rani Sophia (Yeovil District Hospital NHS Foundation Trust), Sion Jones (Betsi Cadwaladr University Health Board), Erica Capps (The Shrewsbury and Telford Hospital NHS Trust), Neil Archibald (South Tees Hospitals NHS Foundation Trust), Louise Wiblin (South Tees Hospitals NHS Foundation Trust), Sean J Slaght (Portsmouth Hospitals NHS Trust), Edward Jones (York Teaching Hospital NHS Foundation Trust), Colin Barnes (Solent NHS Trust), Dominick D'Costa (The Royal Wolverhampton NHS Trust), Carl Mann (Midlands Partnership NHS Foundation Trust), Uma Nath (South Tyneside and Sunderland NHS Foundation Trust), Anette Schrag (Bedfordshire Hospitals NHS Foundation Trust), Dipen Gandecha (St Helens and Knowsley Teaching Hospitals NHS Trust), Gillian Webster (North Cumbria Integrated Care NHS Foundation Trust), Sigurlaug Sveinbjornsdottir (Mid and South Essex NHS Foundation Trust), Lucy Strens (University Hospitals Coventry & Warwickshire), Annette Hand (Northumbria Healthcare NHS Foundation Trust), Richard Walker (Northumbria Healthcare NHS Foundation Trust), Rosemary Crouch (Birmingham Community Healthcare NHS Trust), Jason Raw (Northern Care Alliance NHS Foundation Trust), Stephanie Tuck (Norfolk Community Health & Care NHS Trust), Khaled Amar (University Hospital Dorset NHS Foundation Trust), Emma Wales (Wye Valley NHS Trust), Irene Gentilini (Cambridge University Hospitals NHS

Foundation Trust), Aileen Nacorda (Cambridge University Hospitals NHS Foundation Trust), Louise Hartley (Barts Health NHS Trust)

Clinical research assistants and support staff for sites: Simona Jasaityte (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Miriam Pollard (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Megan Hodgson (University College London Hospitals NHS Foundation Trust, Research Assistant), Clodagh Towns (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Sarah Cable (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Kaylee Gauntlett (Isle of Wight NHS Trust), Deborah Dellafera (Hampshire Hospitals NHS Foundation Trust, Senior Research Nurse), Vicki Fleming (Lancashire Teaching Hospitals NHS Trust, Research Nurse), Judith Dube (University Hospitals Dorset NHS Foundation Trust, Research Nurse), Sarah House (Western Sussex Hospitals NHS Foundation Trust, Clinical Research Practitioner), Caroline Bennett (Harrogate and District NHS Foundation Trust), Helen Casbolt (Sheffield Teaching Hospital NHS Foundation Trust, Clinical Trials Assistant), James Lee (Salisbury NHS Foundation Trust), Laura Parker-Wall (Barking, Havering and Redbridge University Hospitals NHS Trust, Research Nurse), Prisca Mpofu (Leeds Teaching Hospitals NHS Trust, Research Nurse), Dhaval Trivedi (King's College Hospital NHS Foundation Trust), Sofiya Portukhay (The Hillingdon Hospitals NHS Foundation Trust, Clinical Trials Coordinator), Rehanah Roopun (University Hospitals of Leicester NHS Trust, Research Nurse), Lisa Armstrong (Airedale NHS Foundation Trust, Clinical Trials Coordinator), Clare O'Reilly (Royal Devon & Exeter NHS Foundation Trust, Senior Research Nurse), Jonathan Gilby (Livewell Southwest, Senior Research Practitioner), Nishi Singh (Somerset NHS Foundation Trust, Research Nurse), Alison Lewis (Yeovil District Hospital NHS Foundation Trust, research nurse), Julia Roberts (Betsi Cadwaladr University Health Board), Claire Watkins (Betsi Cadwaladr University Health Board), Hannah Gibson (The Shrewsbury and Telford Hospital NHS Trust, Assistant Research Practitioner), Jo Stickley (The Shrewsbury and Telford Hospital NHS Trust, Research Nurse), Catherine Edwards (Portsmouth Hospitals NHS Trust, PD Nurse Specialist), Kerry Elliott (York Teaching Hospital NHS Foundation Trust, Research Nurse), Emma Searle (Solent NHS Trust, Research Nurse), Blessing Okoko (The Royal Wolverhampton NHS Trust, Research Nurse), Susan Wilson (South Tyneside and Sunderland NHS Foundation Trust, Research Nurse), Yvonne Croucher (Bedfordshire Hospitals NHS Foundation Trust), Sharon Dealing (St Helens and Knowsley Teaching Hospitals NHS Trust, Research Nurse), Hannah Martin (University Hospitals Coventry & Warwickshire, Advanced Nurse Practitioner), Claire Williams (Birmingham Community Healthcare NHS Trust, Research Nurse), Lucy Booth (Birmingham Community Healthcare NHS Trust, Research Nurse), Steph Howard (Norfolk Community Health & Care NHS Trust), Rochelle Hernandez (University Hospital Dorset NHS Foundation Trust, Research Nurse), Sue Anderson (Wye Valley NHS Trust, Clinical Trials Nurse), Nosheen Khalid (Barts Health NHS Trust, Clinical Trial Practitioner)



Supplementary Figure 1. Flow diagram of participant exclusions.



Supplementary Figure 2. Percentile of PD polygenic risk scores (PRS) in mutation-negative ($n = 628$) vs mutation-positive PD ($n = 52$). Mutation-negative PD excludes *PINK1* and *PRKN* single heterozygous carriers.

Supplementary Table 1. Demographic characteristics and mutation details of families carrying PD-causing pathogenic mutations

Family ID	Diagnostic category	Sex	Ethnicity	Zygoty	Gene	Variant 1	Variant 2	Additional risk variants	Investigations
1	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
2*	fLOPD	M	Ashkenazi Jewish	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA
3	sEOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
4	sEOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
5	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA
6	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
7	sEOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA, WGS
8^	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA
9^	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
10	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
11	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
12	feOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
13	sEOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
14	sEOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, WGS
15	fLOPD	F	Ashkenazi Jewish	heterozygous	<i>LRRK2</i>	p.G2019S		<i>GBA</i> p.L29Afs*18	NeuroChip, NGS gene panel, WGS
16	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA
17	feOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
18	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA
19	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
20	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, MLPA, WGS
21	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
22	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
23	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
	Unaffected	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
23	Unaffected	F	European	-	-	-			NeuroChip
	Unaffected	F	European	-	-	-			NeuroChip
24	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
25	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
26	fLOPD	F	European	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip
27	fLOPD	F	Ashkenazi Jewish	heterozygous	<i>LRRK2</i>	p.G2019S			NeuroChip, WGS
28	fLOPD	M	NA	heterozygous	<i>LRRK2</i>	p.G2019S			WGS
29	fLOPD	M	European	heterozygous	<i>LRRK2</i>	p.R1441C			NeuroChip, MLPA, WGS
30	sEOPD	M	Ashkenazi Jewish	homozygous	<i>PNPLA6</i>	p.P1297S	p.P1297S		NeuroChip, MLPA, NGS gene panel, WGS
31	feOPD	M	European	compound heterozygous	<i>SPG7</i>	p.N288*	p.A510V		NeuroChip, MLPA, NGS gene panel, WGS
32	sEOPD	F	European	compound heterozygous	<i>PLA2G6</i>	p.T319M	p.L354P		NeuroChip, MLPA, NGS gene panel, WGS
33	feOPD	M	European	compound heterozygous	<i>PRKN</i>	p.C166Y	Exon 1-3 deletion		NeuroChip, MLPA, NGS gene panel
	feOPD	M	European	compound heterozygous	<i>PRKN</i>	p.C253Y	Exon 3-4 deletion		NeuroChip, MLPA, NGS gene panel
34	feOPD	M	European	-	-	-	-		NeuroChip
	feOPD	M	European	-	-	-	-		NeuroChip
	Unaffected	F	European	-	-	-	-		NeuroChip
	Unaffected	M	European	-	-	-	-		NeuroChip

Supplementary Table 1. Demographic characteristics and mutation details of families carrying PD-causing pathogenic mutations

Family ID	Diagnostic category	Sex	Ethnicity	Zygoty	Gene	Variant 1	Variant 2	Additional risk variants	Investigations
35	fEOPD	F	European	compound heterozygous	<i>PRKN</i>	p.Q34Rfs*5	Exon 2 deletion		NeuroChip, MLPA, WGS
36	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.G284R	p.C166Hfs*18		NeuroChip, WGS
37	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.G430D	p.P113fs		NeuroChip, MLPA, WGS
38	sEOPD	F	European	compound heterozygous	<i>PRKN</i>	p.N52Mfs*59	p.W74Cfs*8		NeuroChip, MLPA, NGS gene panel
39*	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.P113fs	Exons 2-3 deletion		NeuroChip, MLPA, NGS gene panel
40	sEOPD	F	European	homozygous	<i>PRKN</i>	p.R275W	p.R275W		NeuroChip, MLPA
	Unaffected	M	European	heterozygous	<i>PRKN</i>	p.R275W	-		NeuroChip
41	fEOPD	F	European	compound heterozygous	<i>PRKN</i>	p.G430D	p.R275W		NeuroChip, MLPA
	Unaffected	F	European	heterozygous	<i>PRKN</i>	p.G430D	-		NeuroChip
42	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.R275W	Exon 3 deletion		NeuroChip, MLPA
	Unaffected	F	European	heterozygous	<i>PRKN</i>	p.R275W	-		NeuroChip
43	Unaffected	F	European	-	-	-	-		NeuroChip
	fEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.R275W	Exon 4 deletion		NeuroChip, MLPA, WGS
44	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.R275W	Exon 4 deletion		NeuroChip, MLPA, NGS gene panel
45	fEOPD	F	European	compound heterozygous	<i>PRKN</i>	p.R275W	Exon 5 deletion		NeuroChip, MLPA
46	fEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.R275W	Exon 8 deletion		NeuroChip, MLPA
47	sEOPD	M	European	homozygous	<i>PRKN</i>	p.R275W	p.R275W		NeuroChip, MLPA
48	fEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.R42P	Exon 3 duplication		NeuroChip, MLPA
49	sEOPD	M	European	compound heterozygous	<i>PRKN</i>	p.T240M & p.P437L	Exon 2 deletion		NeuroChip, MLPA, NGS gene panel, WGS
50	sEOPD	F	South Asian	homozygous	<i>PINK1</i>	p.Y258*	p.Y258*		NeuroChip, MLPA
51	sEOPD	F	European	heterozygous	<i>SNCA</i>	Duplication			NeuroChip, MLPA
52	sEOPD	M	European	heterozygous	<i>SNCA</i>	Duplication			NeuroChip, MLPA
53	fLOPD	M	European	heterozygous	<i>VCP</i>	p.R159C			NeuroChip, MLPA, WGS

NA = Not available, AAO = Age at onset, AAC = age at consent, WGS = whole-genome sequencing, NGS = next-generation sequencing.

*Consanguineous family. ^Families found to be related by kinship analysis.

Supplementary Table 2. Demographic characteristics and mutation details of families carrying a single heterozygous mutation in recessive genes *PINK1* and *PRKN*

Family ID	Diagnostic category	Sex	Ethnicity	Gene	Variant 1	Variant 2	Additional risk variants	Investigations
1*	fEOPD	F	European	<i>PINK1</i>	Exon 1 deletion			NeuroChip, MLPA
	fEOPD	M	European	<i>PINK1</i>	Exon 5 deletion		<i>GBA</i> p.N409S	NeuroChip, MLPA, NGS gene panel, WGS
2	Unaffected	M	European	-	-		<i>GBA</i> p.N409S	NeuroChip
	Unaffected	F	European	-	-		-	NeuroChip
3	fEOPD	F	European	<i>PRKN</i>	p.G430D			NeuroChip, MLPA
	Unaffected	F	European	<i>PRKN</i>	p.G430D			NeuroChip
4	fLOPD	F	European	<i>PRKN</i>	p.K211N			NeuroChip, MLPA, WGS
5	fEOPD	M	South Asian	<i>PRKN</i>	p.Q34fs			NeuroChip, MLPA
6	fEOPD	M	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA, NGS gene panel
7	fEOPD	F	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
	fLOPD	F	European	<i>PRKN</i>	p.P437L	p.P132Tfs*9		NeuroChip, MPLA, NGS gene panel
8	fEOPD	M	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
9	fLOPD	F	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
10	fLOPD	M	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
11	fLOPD	F	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
12	fLOPD	F	European	<i>PRKN</i>	p.P437L			NeuroChip, MLPA
13	fLOPD	M	European	<i>PRKN</i>	p.P437L			NeuroChip, WGS
14	sEOPD	F	European	<i>PRKN</i>	p.R275W			NeuroChip, MLPA
15	fLOPD	M	European	<i>PRKN</i>	p.R275W			NeuroChip, MLPA, WGS
16	sEOPD	M	European	<i>PRKN</i>	p.R275W			NeuroChip, MLPA
	fEOPD	M	European	<i>PRKN</i>	p.R275W			NeuroChip, MLPA
17	fLOPD	F	European	<i>PRKN</i>	p.R275W			NeuroChip
	fLOPD	F	European	<i>PRKN</i>	Exons 1-2 duplication			NeuroChip, MLPA
19	fLOPD	M	Central Asian	<i>PRKN</i>	Exon 2 deletion			NeuroChip, MLPA
20	fLOPD	F	European	<i>PRKN</i>	Exon 2 duplication			NeuroChip, MLPA
21	fLOPD	F	European	<i>PRKN</i>	Exon 2 duplication			NeuroChip, MLPA
22	sEOPD	F	European	<i>PRKN</i>	Exons 2 & 4-7 deletion			NeuroChip, MLPA
23	fEOPD	F	European	<i>PRKN</i>	Exons 3 & 5 deletion			NeuroChip, MLPA
24	fEOPD	M	European	<i>PRKN</i>	Exon 3 deletion			NeuroChip, MLPA
25	sEOPD	M	European	<i>PRKN</i>	Exons 3-4 & 8 deletion			NeuroChip, MLPA, WGS
26	fLOPD	F	European	<i>PRKN</i>	Exons 3-6 duplication			NeuroChip, MLPA
27	fEOPD	M	European	<i>PRKN</i>	Exon 3-6 duplication			NeuroChip, MLPA
28	fEOPD	F	European	<i>PRKN</i>	Exons 3 & 5-7 deletion			NeuroChip, MLPA
29	sEOPD	M	European	<i>PRKN</i>	Exon 8 deletion			NeuroChip, MLPA

NA = Not available, AAO = Age at onset, AAC = age at consent, WGS = whole-genome sequencing, NGS = next-generation sequencing.

* consanguineous family

Supplementary Table 3. Unique PD-associated mutations identified per gene

GBA	LRRK2	PRKN	PINK1	PNPLA6	PLA2G6	SPG7	SNCA	VCP
p.D448H	p.G2019S	p.C166Hfs*18	p.Y258*	p.P1297S	p.T319M	p.N288*	Duplication	p.R159C
p.G152E	p.R1441C	p.C166Y	Exon 1 deletion		p.L354P	p.A510V		
p.G416S		p.C253Y	Exon 5 deletion					
p.L29Afs*18		p.G284R						
p.N409S		p.G430D						
p.P138Lfs*62		p.K211N						
p.P430H		p.N52Mfs*59						
p.R159Q		p.P113fs						
p.R159W		p.P132Tfs*9						
p.R296Q		p.P437L						
p.R398*		p.Q34Rfs*5						
p.R502C		p.R42P						
p.T362I		p.R275W						
		p.T240M						
		p.W74Cfs*8						
		Exons 1-3 deletion						
		Exon 2 deletion						
		Exons 2-3 deletion						
		Exons 2 & 4-7 deletion						
		Exon 3 deletion						
		Exons 3-4 deletion						
		Exons 3 & 5 deletion						
		Exons 3-4 & 8 deletion						
		Exons 3, 5-7 deletion						
		Exon 4 deletion						
		Exon 5 deletion						
		Exon 8 deletion						
		Exons 1-2 duplication						
		Exon 2 duplication						
		Exon 3 duplication						
		Exons 3-6 duplication						

Novel variants are indicated in bold.

Supplementary Table 4. Demographic characteristics of index cases by gene

	<i>SNCA</i>	<i>VCP</i>	<i>LRRK2</i>	<i>PNPLA6</i>	<i>PINK1</i>	<i>SPG7</i>	<i>PLA2G6</i>	<i>PRKN</i>	<i>GBA</i> *	Mutation-negative	P-value
Index cases (N)	2	1	29	1	1	1	1	17	18	614	
Sex (N Female)	1	0	14	0	1	0	1	5	7	259	0.793
Age at Diagnosis (mean ± sd) **	44.5 (0.71) ^d	61-65	58.7 (13.3) ^d	31-35	36-40	41-45	36-40	35.9 (8.70) ^c	50.8 (10.2) ^d	56.8 (13.6)	1.89E-07
Age at Assessment (mean ± sd) **	48.5 (0.71) ^d	66-70	63.9 (11.3) ^d	36-40	51-55	46-50	41-45	49.8 (13.6) ^a	53.8 (10.4) ^a	61.4 (12.8)	4.93E-04
Disease duration at assessment (Years, mean ± sd)	8.5 (4.95) ^d	8	6.86 (4.68)	8	26	20	5	22.6 (14.9) ^b	7.33 (8.74) ^d	8.3 (8.1)	4.27E-04
Genetically Determined Ancestry (%)											0.128
African	0	0	0	0	0	0	0	0	0	0.5	
American	0	0	0	0	0	0	0	0	0	0.5	
Ashkenazi Jewish	0	0	10.3	100	0	0	0	0	11.1	0.6	
Central Asian	0	0	0	0	0	0	0	0	0	0.3	
East Asian	0	0	0	0	0	0	0	0	0	0.2	
European	100	100	86.2	0	0	100	100	100	83.3	93.6	
Middle Eastern	0	0	0	0	0	0	0	0	0	0.3	
South Asian	0	0	0	0	100	0	0	0	0	3.6	
Unknown	0	0	3.5	0	0	0	0	0	5.6	0.3	
Family history (%)											0.025***
No family history	100	0	17.2	100	100	0	100	52.9	22.2	27.4	
One affected relative	0	0	31	0	0	100	0	35.3	55.6	48.0	
Two affected relatives	0	100	27.6	0	0	0	0	11.8	16.7	17.3	
Three or more affected relatives	0	0	24.1	0	0	0	0	0	5.6	7.3	
Self-reported parental consanguinity (%)	0	0	3.8	0	NA	0	0	7.14	0	0.89	0.123

*Excludes one case with concomitant *LRRK2* p.G2019S mutation and one case with concomitant *PINK1* heterozygous exon 5 deletion. **When N = 1, Age at Diagnosis and Age at Assessment are presented as a 5-year age bracket. NA = not available. Continuous variables were compared with Kruskal-Wallis test with FDR-adjusted P-values for multiple comparisons. Significance levels show comparison with mutation-negative group only: a, P<0.05. b, P<0.001. c, P<0.0001. d, not significant. Categorical variables were compared with Fisher's exact test. Only genes with N≥2 were tested. ***No significant P-values after FDR-adjusted pairwise comparisons across genes.

Supplementary Table 5. Genetic testing methods by disease category of index case

N (%)	sEOPD n =196	fEOPD n = 112	fLOPD n =406	Total N = 714
NeuroChip SNP array	194 (99.0)	111 (99.1)	404 (99.5)	709 (99.3)
MLPA assay	178 (90.8)	107 (95.5)	255 (62.8)	540 (75.6)
Gene panel or whole-genome sequencing	43 (21.9)	31 (27.7)	62 (15.3)	136 (19.0)

Supplementary Table 6. Demographic characteristics and mutation details of families carrying a heterozygous mutation in *GBA*

Family ID	Diagnosis	Sex	Ethnicity	Gene	Variant	Additional variants	Investigations
1	fLOPD	F	European	<i>GBA</i>	p.D448H		NeuroChip, MLPA
2	sEOPD	M	European	<i>GBA</i>	p.G152E		NeuroChip, MLPA, WGS
3	fEOPD	F	European	<i>GBA</i>	p.G416S		NeuroChip, MLPA, NGS gene panel, WGS
4	fLOPD	F	European	<i>GBA</i>	p.N409S		NeuroChip
5	fEOPD	M	European	<i>GBA</i>	p.N409S	<i>PINK1</i> exon5 deletion	NeuroChip, MLPA, NGS gene panel, WGS
	Unaffected	M	European	<i>GBA</i>	p.N409S		NeuroChip
	Unaffected	F	European	-	-		NeuroChip
6	fLOPD	F	European	<i>GBA</i>	p.N409S		NeuroChip, MLPA
7	fEOPD	M	Ashkenazi Jewish	<i>GBA</i>	p.N409S		NeuroChip, MLPA
	Unaffected	F	European	<i>GBA</i>	p.N409S		NeuroChip
8	sEOPD	M	Ashkenazi Jewish	<i>GBA</i>	p.N409S		NeuroChip, MLPA
9	sEOPD	F	NA	<i>GBA</i>	p.P138Lfs*62		WGS
10	fLOPD	M	European	<i>GBA</i>	p.P430H		NeuroChip, WGS
11	fLOPD	M	European	<i>GBA</i>	p.R159Q		NeuroChip, MLPA, WGS
12	fEOPD	M	European	<i>GBA</i>	p.R159W		NeuroChip, MLPA, WGS
	fEOPD	M	European	<i>GBA</i>	p.R296Q		NeuroChip, MLPA
13	Unaffected	F	European	<i>GBA</i>	p.R296Q		NeuroChip
	Unaffected	F	European	<i>GBA</i>	p.R296Q		NeuroChip
14	fLOPD	F	European	<i>GBA</i>	p.R398*		NeuroChip
15	fLOPD	F	European	<i>GBA</i>	p.R502C		NeuroChip
16	fLOPD	M	European	<i>GBA</i>	p.R502C		NeuroChip, MLPA
17	fLOPD	M	European	<i>GBA</i>	p.R502C		NeuroChip, MLPA
18	sEOPD	M	European	<i>GBA</i>	p.R502C		NeuroChip
19	fEOPD	M	European	<i>GBA</i>	p.T362I		NeuroChip
20	fLOPD	F	Ashkenazi Jewish	<i>GBA</i>	p.L29Afs*18	<i>LRRK2</i> p.G2019S	NeuroChip, NGS gene panel, WGS

NA = Not available, AAO = Age at onset, AAC = age at consent, WGS = whole-genome sequencing, NGS = next-generation sequencing.

Supplementary Table 7. PD-associated SNPs with probes in NeuroChip

Gene	Chr	c.DNA	Protein change	Clinvar classification	MDSGene classification
<i>PRKN</i>	6	c.1359G>A	p.Trp453*	Likely pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.1292G>T	p.Cys431Phe	Pathogenic	
<i>PRKN</i>	6	c.1289G>A	p.Gly430Asp	Pathogenic	
<i>PRKN</i>	6	c.931C>T	p.Gln311*	Pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.850G>C	p.Gly284Arg	Pathogenic	
<i>PRKN</i>	6	c.823C>T	p.Arg275Trp	Pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.635G>A	p.Cys212Tyr	Pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.633A>T	p.Lys211Asn	Pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.483A>T	p.Lys161Asn	Pathogenic	
<i>PRKN</i>	6	c.98G>A	p.Arg33Gln	Pathogenic	
<i>PRKN</i>	6	c.1334G>A	p.Trp445*	Pathogenic	
<i>PRKN</i>	6	c.1321T>C	p.Cys441Arg	Pathogenic	
<i>PRKN</i>	6	c.1252T>C	p.Cys418Arg	Likely pathogenic	
<i>PRKN</i>	6	c.1244C>A	p.Thr415Asn	Likely pathogenic	
<i>PRKN</i>	6	c.125G>C	p.Arg42Pro	Pathogenic	Definitely pathogenic
<i>PRKN</i>	6	c.865T>G	p.Cys289Gly		Definitely pathogenic
<i>PRKN</i>	6	c.1310C>T	p.Pro437Leu	Conflicting interpretations	Definitely pathogenic
<i>PRKN</i>	6	c.101_102del	p.Gln34fs	Pathogenic	
<i>PRKN</i>	6	c.220_221dup	p.Trp74fs	Pathogenic/Likely pathogenic	
<i>PINK1</i>	1	c.502G>C	p.Ala168Pro	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.650C>A	p.Ala217Asp	Pathogenic	
<i>PINK1</i>	1	c.736C>T	p.Arg246*	Pathogenic	
<i>PINK1</i>	1	c.774C>A	p.Tyr258*	Pathogenic	
<i>PINK1</i>	1	c.813C>A	p.His271Gln	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.926G>A	p.Gly309Asp	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.938C>T	p.Thr313Met	Pathogenic	
<i>PINK1</i>	1	c.1040T>C	p.Leu347Pro	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.1311G>A	p.Trp437*	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.1366C>T	p.Gln456*	Pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.1474C>T	p.Arg492*	Pathogenic	
<i>PINK1</i>	1	c.1162T>C	p.Cys388Arg	Likely pathogenic	Definitely pathogenic
<i>PINK1</i>	1	c.377A>C	p.Gln126Pro	Likely pathogenic	
<i>PINK1</i>	1	c.509T>G	p.Val170Gly		Definitely pathogenic
<i>PINK1</i>	1	c.718G>A	p.Glu240Lys		Definitely pathogenic
<i>PINK1</i>	1	c.1226G>T	p.Gly409Val		Definitely pathogenic
<i>PINK1</i>	1	c.1250A>G	p.Glu417Gly		Definitely pathogenic
<i>PARK7</i>	1	c.29T>C	p.Leu10Pro		Definitely pathogenic
<i>PARK7</i>	1	c.78G>A	p.Met26Ile	Pathogenic	Definitely pathogenic
<i>PARK7</i>	1	c.115G>T	p.Ala39Ser	Pathogenic	
<i>PARK7</i>	1	c.192G>C	p.Glu64Asp	Pathogenic	Definitely pathogenic
<i>PARK7</i>	1	c.497T>C	p.Leu166Pro	Pathogenic	Definitely pathogenic
<i>PARK7</i>	1	c.133C>T	p.Gln45*	Pathogenic	
<i>ATP13A2</i>	1	c.2629G>A	p.Gly877Arg	Pathogenic	
<i>ATP13A2</i>	1	c.2561T>G	p.Met854Arg	Pathogenic	
<i>ATP13A2</i>	1	c.1903C>T	p.Gln635*	Pathogenic	
<i>ATP13A2</i>	1	c.3176T>G	p.Leu1059Arg	Likely pathogenic	Definitely pathogenic
<i>ATP13A2</i>	1	c.2529+1G>A	NA	Likely pathogenic	
<i>ATP13A2</i>	1	c.477+2T>G	NA	Pathogenic/Likely pathogenic	
<i>ATP13A2</i>	1	c.2113C>T	p.Gln705Ter	Pathogenic	
<i>FBXO7</i>	22	c.65C>T	p.Thr22Met	Pathogenic	Definitely pathogenic
<i>FBXO7</i>	22	c.1492C>T	p.Arg498*	Pathogenic	Definitely pathogenic
<i>FBXO7</i>	22	c.961C>T	p.Arg321*	Likely pathogenic	
<i>FBXO7</i>	22	c.1033C>T	p.Arg345*	Likely pathogenic	
<i>SNCA</i>	4	c.157G>A	p.Ala53Thr	Pathogenic	Definitely pathogenic
<i>SNCA</i>	4	c.152G>A	p.Gly51Asp	Pathogenic	Definitely pathogenic
<i>SNCA</i>	4	c.136G>A	p.Glu46Lys	Pathogenic	
<i>SNCA</i>	4	c.88G>C	p.Ala30Pro	Pathogenic	
<i>LRRK2</i>	12	c.3364A>G	p.Ile1122Val	Pathogenic	
<i>LRRK2</i>	12	c.4321C>T	p.Arg1441Cys	Pathogenic	Definitely pathogenic
<i>LRRK2</i>	12	c.5096A>G	p.Tyr1699Cys	Pathogenic	Definitely pathogenic
<i>LRRK2</i>	12	c.6055G>A	p.Gly2019Ser	Pathogenic	Definitely pathogenic
<i>LRRK2</i>	12	c.6059T>C	p.Ile2020Thr	Pathogenic	Definitely pathogenic
<i>VPS35</i>	16	c.1858G>A	p.Asp620Asn	Pathogenic	Definitely pathogenic
<i>DCTN1</i>	2	c.221A>C	p.Gln74Pro	Pathogenic	
<i>DCTN1</i>	2	c.212G>A	p.Gly71Glu	Pathogenic	
<i>DCTN1</i>	2	c.211G>A	p.Gly71Arg	Pathogenic	Definitely pathogenic
<i>DCTN1</i>	2	c.200G>A	p.Gly67Asp	Pathogenic	
<i>DCTN1</i>	2	c.175G>A	p.Gly59Ser	Pathogenic	
<i>DCTN1</i>	2	c.156T>G	p.Phe52Leu	Pathogenic	

Supplementary Table 7. PD-associated SNPs with probes in NeuroChip

Gene	Chr	c.DNA	Protein change	Clinvar classification	MDSGene classification
<i>DCTN1</i>	2	c.3823C>T	p.Arg1275Cys	Likely pathogenic	
<i>DCTN1</i>	2	c.175G>C	p.Gly59Arg	Pathogenic	
<i>VCP</i>	9	c.695C>A	p.Ala232Glu	Pathogenic	
<i>VCP</i>	9	c.572G>A	p.Arg191Gln	Pathogenic/Likely pathogenic	
<i>VCP</i>	9	c.476G>A	p.Arg159His	Pathogenic	
<i>VCP</i>	9	c.475C>T	p.Arg159Cys	Pathogenic	
<i>VCP</i>	9	c.463C>T	p.Arg155Cys	Pathogenic	
<i>VCP</i>	9	c.283C>G	p.Arg95Gly	Pathogenic	
<i>VCP</i>	9	c.277C>T	p.Arg93Cys	Pathogenic	
<i>VCP</i>	9	c.472A>G	p.Met158Val	Pathogenic	
<i>VCP</i>	9	c.469G>C	p.Gly157Arg	Pathogenic	
<i>VCP</i>	9	c.284G>A	p.Arg95His	Likely pathogenic	
<i>VCP</i>	9	c.278G>A	p.Arg93His	Likely pathogenic	
<i>VCP</i>	9	c.553G>A	p.Glu185Lys	Likely pathogenic	
<i>VCP</i>	9	c.466G>A	p.Gly156Ser	Pathogenic	
<i>GBA</i>	1	c.1549G>A	p.Gly517Ser	Pathogenic	
<i>GBA</i>	1	c.1505G>A	p.Arg502His	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1504C>T	p.Arg502Cys	Pathogenic	
<i>GBA</i>	1	c.1503C>G	p.Asn501Lys	Likely pathogenic	
<i>GBA</i>	1	c.1448T>G	p.Leu483Arg	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1342G>C	p.Asp448His	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1297G>T	p.Val433Leu	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1271T>C	p.Leu424Pro	Likely pathogenic	
<i>GBA</i>	1	c.1246G>A	p.Gly416Ser	Pathogenic	
<i>GBA</i>	1	c.1228C>G	p.Leu410Val	Pathogenic	
<i>GBA</i>	1	c.1226A>G	p.Asn409Ser	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1208G>C	p.Ser403Thr	Likely pathogenic	
<i>GBA</i>	1	c.1192C>T	p.Arg398*	Pathogenic	
<i>GBA</i>	1	c.1174C>T	p.Arg392Trp	Pathogenic	
<i>GBA</i>	1	c.1174C>G	p.Arg392Gly	Pathogenic	
<i>GBA</i>	1	c.1171G>C	p.Val391Leu	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1090G>A	p.Gly364Arg	Likely pathogenic	
<i>GBA</i>	1	c.1085C>T	p.Thr362Ile	Pathogenic	
<i>GBA</i>	1	c.983C>T	p.Pro328Leu	Pathogenic	
<i>GBA</i>	1	c.928A>G	p.Ser310Gly	Likely pathogenic	
<i>GBA</i>	1	c.896T>C	p.Ile299Thr	Likely pathogenic	
<i>GBA</i>	1	c.887G>A	p.Arg296Gln	Pathogenic	
<i>GBA</i>	1	c.870C>A	p.Phe290Leu	Pathogenic	
<i>GBA</i>	1	c.764T>A	p.Phe255Tyr	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.709A>G	p.Lys237Glu	Pathogenic	
<i>GBA</i>	1	c.703T>C	p.Ser235Pro	Pathogenic	
<i>GBA</i>	1	c.701G>A	p.Gly234Glu	Likely pathogenic	
<i>GBA</i>	1	c.681T>G	p.Asn227Lys	Pathogenic	
<i>GBA</i>	1	c.680A>G	p.Asn227Ser	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.625C>T	p.Arg209Cys	Pathogenic	
<i>GBA</i>	1	c.509G>T	p.Arg170Leu	Likely pathogenic	
<i>GBA</i>	1	c.497A>T	p.Asp166Val	Likely pathogenic	
<i>GBA</i>	1	c.475C>T	p.Arg159Trp	Pathogenic	
<i>GBA</i>	1	c.415G>C	p.Ala139Pro	Likely pathogenic	
<i>GBA</i>	1	c.254G>A	p.Gly85Glu	Pathogenic	
<i>GBA</i>	1	c.160G>T	p.Val54Leu	Pathogenic	
<i>GBA</i>	1	c.914C>T	p.Pro305Leu	Likely pathogenic	
<i>GBA</i>	1	c.894C>A	p.Phe298Leu	Likely pathogenic	
<i>GBA</i>	1	c.1342G>C	p.Asp448His	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.1249T>G	p.Trp417Gly	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.661C>A	p.Pro221Thr	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.314T>C	p.Leu105Pro	Likely pathogenic	
<i>GBA</i>	1	c.1300C>T	p.Arg434Cys	Likely pathogenic	
<i>GBA</i>	1	c.1162G>A	p.Glu388Lys	Likely pathogenic	
<i>GBA</i>	1	c.721G>A	p.Gly241Arg	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.721G>A	p.Gly241Arg	Pathogenic/Likely pathogenic	
<i>GBA</i>	1	c.84dup	p.Leu29fs	Pathogenic	

NA=not applicable. Pathogenic SNPs in genes associated with monogenic PD, classified by ClinVar as pathogenic/likely pathogenic and/or MDSGene as definitively pathogenic. GBA variants classified by ClinVar as pathogenic for Gaucher's disease or risk factors for PD.